Brazil’s Spiraling Access Suits And The Potential Impact On Companies
Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.
You may also be interested in...
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
As Brazil turns to risk sharing agreements to improve access to expensive treatments, the health ministry has its eye on Biogen’s rare disease treatment Spinraza (nusinersen).
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.